News

Freddie Mac's STACR 2025-DNA1 Receives KBRA Preliminary Ratings

Freddie Mac's STACR 2025-DNA1 Receives KBRA Preliminary Ratings

Freddie Mac's STACR 2025-DNA1 Sees New Ratings from KBRA

KBRA has recently assigned preliminary ratings to a notable transaction involving Freddie Mac's Structured Agency Credit Risk (STACR) program. This particular set of ratings pertains to the STACR REMIC Trust 2025-DNA1 Notes, amounting to an impressive $675,500,000 in total note offerings. The STACR 2025-DNA1 continues to shed light on Freddie Mac's efforts in credit risk sharing while ensuring stability within the mortgage market.

Details of the Credit Risk Sharing Transaction

The STACR 2025-DNA1 features mortgages that possess loan-to-value (LTV) ratios that exceed 60% but remain at or below 80%. These notes are backed by a robust Reference Pool, which consists of 57,034 residential mortgage loans. As of the cut-off date, the total outstanding principal balance of the Reference Pool is approximately $18.7 billion, reflecting the significant scale of this transaction.

Quality and Composition of the Reference Pool

Focusing on quality, the Reference Obligations within the pool feature fully-documented, fully-amortizing 30-year fixed-rate mortgages (FRMs) which are of prime quality. Borrowers in this pool are not only vetted thoroughly, but they also showcase a weighted average (WA) original credit score of 757. In terms of financial health, the New Zealand weighted average (NZWA) debt-to-income (DTI) ratio stands at a manageable 38.4%. These metrics indicate that the pool is composed of responsible borrowers, which further enhances the reliability of the investment.

Analytical Approach by KBRA

KBRA's approach to rating this substantial transaction involved an in-depth loan-level analysis using its proprietary KBRA RMBS Credit Model and Residential Asset Loss Model (REALM). They utilized cash flow modeling techniques to assess the transaction's payment structure, while also incorporating findings from comprehensive third-party loan file due diligence. All these components work together to form a holistic view of the credit quality and potential risk associated with the STACR 2025-DNA1.

Legal Framework and Documentation Review

Moreover, KBRA conducted thorough reviews of essential parties involved in the transaction as well as a critical assessment of its legal structure and documentation. This all-encompassing analytical rigor ensures that all potential risks are considered, leading to more accurate and effective ratings.

Accessing Ratings and Additional Information

To gain insights into the ratings and various relevant documents, interested parties can easily access the data through official channels. KBRA has made it straightforward for researchers and stakeholders to obtain all necessary details as this transaction unfolds.

About KBRA

Kroll Bond Rating Agency, LLC (KBRA) operates as a comprehensive credit rating agency, recognized and officially registered with the U.S. Securities and Exchange Commission as an NRSRO. The agency also has international credibility, with subsidiaries established in Europe and the UK that meet regulatory requirements. KBRA's rigorous credit rating processes have made them a trusted name in the financial industry.

Frequently Asked Questions

What is the STACR 2025-DNA1?

The STACR 2025-DNA1 is a credit risk-sharing transaction from Freddie Mac involving structured agency credit risk.

What does KBRA's preliminary rating indicate?

KBRA's preliminary rating reflects the perceived credit quality and risk associated with the STACR 2025-DNA1 transaction, aiding investors in making informed decisions.

What kind of mortgages back the STACR 2025-DNA1?

The STACR 2025-DNA1 is backed by fully documented, fully amortizing, primarily 30-year fixed-rate mortgages.

What is the significance of LTV ratios in this context?

LTV ratios are crucial as they provide insights into the risk level of the mortgages; in this case, they range from over 60% to no more than 80%.

How can I find more information about KBRA's ratings?

More information regarding KBRA's ratings can be accessed through their official website and related publications on their transactions.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

AEVEX Faces 48-Hour Deadline for Investor Class Action

Updated Category News Views 11

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Continue Reading
Lundbeck's Board Leadership Transitions into New Era

Updated Category News Views 9

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Continue Reading
Faith and Resilience in China: The Legacy of the Long March

Updated Category News Views 14

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Continue Reading
Antheia Secures $80M for Critical Medicine Onshoring

Updated Category News Views 20

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Continue Reading
Tomorrowland's Shanghai Return: An Electri-Lifesaver

Updated Category News Views 21

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Continue Reading
ASTS Faces a Legal Countdown – Investors Take Note

Updated Category News Views 10

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Continue Reading
UEG's New Advisory Board: Elevating Patient Voices

Updated Category News Views 19

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Continue Reading

Top 5 Most Recently Viewed Articles

Sera Prognostics to Showcase Innovations at RBC Healthcare Event

Updated Category News Views 112

Sera Prognostics to Showcase Innovations at RBC Healthcare Event Sera Prognostics Inc., known as The Pregnancy Company (NASDAQ: SERA), is focused on enhancing maternal and neonatal health through innovative pregnancy biomarker information. The company has recently announced its participation at an important healthcare event, highlighting its ongoing commitment to improve...

Continue Reading
Unlocking AI Potential: Insights from Netcracker CEO Andrew Feinberg

Updated Category News Views 268

Exciting Keynote at GITEX Global 2024 Netcracker Technology is buzzing with excitement as Andrew Feinberg, the Chairman and CEO, prepares for a pivotal keynote presentation at one of the largest tech events in the world, GITEX Global 2024. This annual technology conference draws innovators, industry leaders, and enthusiasts keen on understanding the future of technology....

Continue Reading
Adherium Empowers COPD and Asthma Management with iCARE Study

Updated Category News Views 147

Adherium's Transformative iCARE Study Results The innovative strides made by Adherium Limited (ASX:ADR) in respiratory health have shown promising outcomes as seen in the iCARE study. This study investigated the effectiveness of their Hailie® Smartinhaler® technology in improving adherence among patients suffering from chronic obstructive pulmonary disease (COPD) and...

Continue Reading
Medius Highlights Impending Finance Challenges Post AI Launch

Updated Category News Views 243

AI Fraud Concerns Elevate in the Finance Sector Medius has unveiled alarming findings indicating that nearly one in three finance professionals are unable to spot AI-generated fake receipts. This revelation surfaces amidst rising fears of fraud escalation following the recent launch of GPT-5.0. With the capabilities of AI continuously improving, finance teams must prepare...

Continue Reading
TD Cowen Sustainably Endorses Abbott Labs with Robust Price Target

Updated Category News Views 59

TD Cowen Affirms Buy Rating on Abbott Laboratories TD Cowen has reaffirmed its Buy rating on Abbott Laboratories (NYSE: ABT), maintaining a price target of $130.00 for the healthcare company's shares. This positive stance hinges on expectations that Abbott's upcoming third-quarter results will either meet or surpass current market predictions, allowing the company to...

Continue Reading